In the present meta-analysis, we found no significant differences in all-cause mortality at 14 days or 28 days, in-hospital mortality, or adverse events between the G-CSF or GM-CSF group and placebo group in adult patients with sepsis. The gene discussed is CSF3; the disease is Sepsis.